Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis

Sifan Sun1, Hailiang Fang2

  • 1Department of Rehabilitation, The Second Hospital of Dalian Medical University, Dalian City, Liaoning Province, China.

Journal of Ovarian Research
|November 17, 2021
PubMed
Abstract

Insights

Curcumin inhibits ovarian cancer by regulating the circ-PLEKHM3/miR-320a/SMG1 pathway. This study clarifies curcumin

Area of Science:

  • Molecular Oncology
  • Biochemistry

Background:

  • Curcumin shows potential in ovarian cancer therapy.
  • The precise molecular mechanisms, particularly involving the circRNA/miRNA/mRNA network, remain unclear.

Purpose of the Study:

  • To investigate the role of curcumin in ovarian cancer.
  • To elucidate the involvement of the circ-PLEKHM3/miR-320a/SMG1 axis in curcumin's anti-cancer effects.

Main Methods:

  • Quantitative real-time PCR (qRT-PCR) for gene expression analysis.
  • Cell viability, apoptosis, and colony formation assays.
  • Western blot, dual-luciferase reporter assays, and RIP assays.

Main Results:

  • Curcumin suppressed ovarian cancer cell proliferation and induced apoptosis.
  • Circ-PLEKHM3 was downregulated in ovarian cancer and its expression was increased by curcumin.
  • Circ-PLEKHM3 acts as a sponge for miR-320a, which targets SMG1, forming a regulatory axis.

Conclusions:

  • Curcumin exerts anti-cancer effects in ovarian cancer by modulating the circ-PLEKHM3/miR-320a/SMG1 axis.
  • This pathway represents a potential therapeutic target for ovarian cancer treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K